Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urelumab (BMS-663513) in previously treated advanced melanoma
NCT00612664Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2008
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of urelumab in melanoma, sponsored by Bristol Myers Squibb. Started Mar 2008; status: completed.
02
Drugs
urelumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00612664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00612664.